MicroRNAs and Cancer Metabolism Reprogramming: the Paradigm of Metformin

Overview

Journal Ann Transl Med

Publisher AME Publishing Company

Date 2014 Oct 22

PMID 25333033

Citations 24

Authors

Claudio Pulito

Sara Donzelli

Paola Muti

Luisa Puzzo

Sabrina Strano

Giovanni Blandino

Affiliations

Soon will be listed here.

Abstract

Increasing evidence witnesses that cancer metabolism alterations represent a critical hallmark for many types of human tumors. There is a strong need to understand and dissect the molecular mechanisms underlying cancer metabolism to envisage specific biomarkers and underpin critical molecular components that might represent novel therapeutic targets. One challenge, that is the focus of this review, is the reprogramming of the altered metabolism of a cancer cell toward that of un-transformed cell. The anti-hyperglicemic agent, metformin has proven to be effective in reprogramming the metabolism of cancer cells even from those subpopulations endowed with cancer stem like features and very high chemoresistenace to conventional anticancer treatments. A functional interplay involving selective modulation of microRNAs (miRNAs) takes place along the anticancer metabolic effects exerted by metformin. The implications of this interplay will be also discussed in this review.

Citing Articles

Metformin as a potential agent for modulating the faulty endometriotic mesenchymal stem cells: A case-control study.

Mashayekhi P, Noruzinia M, Khodaverdi S Int J Reprod Biomed. 2022; 20(10):861-872.

PMID: 36381355 PMC: 9644643. DOI: 10.18502/ijrm.v20i10.12270.

The role and mechanism of noncoding RNAs in regulation of metabolic reprogramming in hepatocellular carcinoma.

Liao W, Du J, Wang Z, Feng Q, Liao M, Liu H Int J Cancer. 2022; 151(3):337-347.

PMID: 35460073 PMC: 9325518. DOI: 10.1002/ijc.34040.

The role of AMPK-dependent pathways in cellular and molecular mechanisms of metformin: a new perspective for treatment and prevention of diseases.

Hasanvand A Inflammopharmacology. 2022; 30(3):775-788.

PMID: 35419709 PMC: 9007580. DOI: 10.1007/s10787-022-00980-6.

Metformin - a new approach.

Cwynar-Zajac L Pediatr Endocrinol Diabetes Metab. 2021; 27(2):134-140.

PMID: 34514769 PMC: 10214935. DOI: 10.5114/pedm.2021.107166.

Metformin and Biliary Tract Cancer in Patients With Type 2 Diabetes.

Tseng C Front Oncol. 2020; 10:587666.

PMID: 33194743 PMC: 7653020. DOI: 10.3389/fonc.2020.587666.

References

Stephenne X, Foretz M, Taleux N, van der Zon G, Sokal E, Hue L . Metformin activates AMP-activated protein kinase in primary human hepatocytes by decreasing cellular energy status. Diabetologia. 2011; 54(12):3101-10. PMC: 3210354. DOI: 10.1007/s00125-011-2311-5. View

Kalender A, Selvaraj A, Kim S, Gulati P, Brule S, Viollet B . Metformin, independent of AMPK, inhibits mTORC1 in a rag GTPase-dependent manner. Cell Metab. 2010; 11(5):390-401. PMC: 3081779. DOI: 10.1016/j.cmet.2010.03.014. View

Lee Y, Kim M, Han J, Yeom K, Lee S, Baek S . MicroRNA genes are transcribed by RNA polymerase II. EMBO J. 2004; 23(20):4051-60. PMC: 524334. DOI: 10.1038/sj.emboj.7600385. View

Shu Y, Sheardown S, Brown C, Owen R, Zhang S, Castro R . Effect of genetic variation in the organic cation transporter 1 (OCT1) on metformin action. J Clin Invest. 2007; 117(5):1422-31. PMC: 1857259. DOI: 10.1172/JCI30558. View

Menendez J, Cufi S, Oliveras-Ferraros C, Martin-Castillo B, Joven J, Vellon L . Metformin and the ATM DNA damage response (DDR): accelerating the onset of stress-induced senescence to boost protection against cancer. Aging (Albany NY). 2011; 3(11):1063-77. PMC: 3249452. DOI: 10.18632/aging.100407. View

Smith M, Lee H, Nathan D . Insulin sensitivity during combined androgen blockade for prostate cancer. J Clin Endocrinol Metab. 2006; 91(4):1305-8. DOI: 10.1210/jc.2005-2507. View

Blandino G, Valerio M, Cioce M, Mori F, Casadei L, Pulito C . Metformin elicits anticancer effects through the sequential modulation of DICER and c-MYC. Nat Commun. 2012; 3:865. DOI: 10.1038/ncomms1859. View

Pasquinelli A . MicroRNAs and their targets: recognition, regulation and an emerging reciprocal relationship. Nat Rev Genet. 2012; 13(4):271-82. DOI: 10.1038/nrg3162. View

Quattrini I, Conti A, Pazzaglia L, Novello C, Ferrari S, Picci P . Metformin inhibits growth and sensitizes osteosarcoma cell lines to cisplatin through cell cycle modulation. Oncol Rep. 2013; 31(1):370-5. DOI: 10.3892/or.2013.2862. View

10.

Quintavalle C, Garofalo M, Zanca C, Romano G, Iaboni M, Del Basso De Caro M . miR-221/222 overexpession in human glioblastoma increases invasiveness by targeting the protein phosphate PTPμ. Oncogene. 2011; 31(7):858-68. PMC: 4299860. DOI: 10.1038/onc.2011.280. View

11.

Foretz M, Hebrard S, Leclerc J, Zarrinpashneh E, Soty M, Mithieux G . Metformin inhibits hepatic gluconeogenesis in mice independently of the LKB1/AMPK pathway via a decrease in hepatic energy state. J Clin Invest. 2010; 120(7):2355-69. PMC: 2898585. DOI: 10.1172/JCI40671. View

12.

Cufi S, Vazquez-Martin A, Oliveras-Ferraros C, Quirantes R, Segura-Carretero A, Micol V . Metformin lowers the threshold for stress-induced senescence: a role for the microRNA-200 family and miR-205. Cell Cycle. 2012; 11(6):1235-46. DOI: 10.4161/cc.11.6.19665. View

13.

le Sage C, Nagel R, Egan D, Schrier M, Mesman E, Mangiola A . Regulation of the p27(Kip1) tumor suppressor by miR-221 and miR-222 promotes cancer cell proliferation. EMBO J. 2007; 26(15):3699-708. PMC: 1949005. DOI: 10.1038/sj.emboj.7601790. View

14.

Kai Y, Peng W, Ling W, Jiebing H, Zhuan B . Reciprocal effects between microRNA-140-5p and ADAM10 suppress migration and invasion of human tongue cancer cells. Biochem Biophys Res Commun. 2014; 448(3):308-14. DOI: 10.1016/j.bbrc.2014.02.032. View

15.

Algire C, Amrein L, Bazile M, David S, Zakikhani M, Pollak M . Diet and tumor LKB1 expression interact to determine sensitivity to anti-neoplastic effects of metformin in vivo. Oncogene. 2010; 30(10):1174-82. DOI: 10.1038/onc.2010.483. View

16.

Kim V, Han J, Siomi M . Biogenesis of small RNAs in animals. Nat Rev Mol Cell Biol. 2009; 10(2):126-39. DOI: 10.1038/nrm2632. View

17.

Bowker S, Majumdar S, Veugelers P, Johnson J . Increased cancer-related mortality for patients with type 2 diabetes who use sulfonylureas or insulin: Response to Farooki and Schneider. Diabetes Care. 2006; 29(8):1990-1. DOI: 10.2337/dc06-0997. View

18.

Wang B, Herman-Edelstein M, Koh P, Burns W, Jandeleit-Dahm K, Watson A . E-cadherin expression is regulated by miR-192/215 by a mechanism that is independent of the profibrotic effects of transforming growth factor-beta. Diabetes. 2010; 59(7):1794-802. PMC: 2889781. DOI: 10.2337/db09-1736. View

19.

Yang H, Fang F, Chang R, Yang L . MicroRNA-140-5p suppresses tumor growth and metastasis by targeting transforming growth factor β receptor 1 and fibroblast growth factor 9 in hepatocellular carcinoma. Hepatology. 2013; 58(1):205-17. DOI: 10.1002/hep.26315. View

20.

Kobayashi M, Kato K, Iwama H, Fujihara S, Nishiyama N, Mimura S . Antitumor effect of metformin in esophageal cancer: in vitro study. Int J Oncol. 2012; 42(2):517-24. DOI: 10.3892/ijo.2012.1722. View